Patents by Inventor Yawei Ni
Yawei Ni has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230330205Abstract: A dry powder Norovirus vaccine is provided, which comprises at least two Norovirus antigens representing different genogroups. The vaccine may be produced by formulation with a mixture of different antigens or combination of monovalent powders with each containing one antigen. The formulated vaccine is suitable for mucosal administration and soluble in aqueous solutions for parenteral administration. A method of immunization is also provided, which comprises at least one administration of the vaccine via mucosal and/or parental route. The immunization may have multiple administrations of the vaccine, i.e., one or more immunizations via a mucosal route followed by one or more immunizations via a parenteral route or vice versa, to maximize both mucosal and systemic immune responses and protection against Norovirus infections.Type: ApplicationFiled: February 2, 2023Publication date: October 19, 2023Inventors: Ron COBB, Michael SPRINGER, Yawei NI
-
Patent number: 11596680Abstract: A dry powder norovirus vaccine is provided, which comprises at least two norovirus antigens representing different genogroups. The vaccine may be produced by formulation with a mixture of different antigens or combination of monovalent powders with each containing one antigen. The formulated vaccine is suitable for mucosal administration and soluble in aqueous solutions for parenteral administration. A method of immunization is also provided, which comprises at least one administration of the vaccine via mucosal and/or parental route. The immunization may have multiple administrations of the vaccine, i.e., one or more immunizations via a mucosal route followed by one or more immunizations via a parenteral route or vice versa, to maximize both mucosal and systemic immune responses and protection against norovirus infections.Type: GrantFiled: May 18, 2020Date of Patent: March 7, 2023Assignee: RESILIENCE GOVERNMENT SERVICES, INC.Inventors: Ron Cobb, Michael Springer, Yawei Ni
-
Patent number: 11219682Abstract: Novel nanoparticle fusion proteins comprising proteins or peptides fused to Dps (DNA binding protein from starved cells) proteins are provided which bring forth distinct advantages for development of new and improved vaccines, diagnostic tests, and other biomedical products.Type: GrantFiled: February 9, 2018Date of Patent: January 11, 2022Assignee: KJ Biosciences LLCInventor: Yawei Ni
-
Patent number: 10912825Abstract: An influenza vaccine comprising an influenza hemagglutinin-containing antigen which is subjected to a treatment at a suitable low pH or other suitable conditions to obtain a suitable degree of loss of potency, and the method of making it are provided. The vaccine not only induces an increased cross-reactive immune response and cross protection, but can also induce a strain-specific immune response and protection like current inactivated vaccines. A method of administering influenza vaccines is also provided to induce an increased cross-reactive immune response and cross protection, which is especially suitable for use in emergency situations such as a pandemic.Type: GrantFiled: January 14, 2019Date of Patent: February 9, 2021Assignee: KJ Biosciences LLCInventors: Yawei Ni, Jianhua Guo
-
Publication number: 20200345828Abstract: A dry powder norovirus vaccine is provided, which comprises at least two norovirus antigens representing different genogroups. The vaccine may be produced by formulation with a mixture of different antigens or combination of monovalent powders with each containing one antigen. The formulated vaccine is suitable for mucosal administration and soluble in aqueous solutions for parenteral administration. A method of immunization is also provided, which comprises at least one administration of the vaccine via mucosal and/or parental route. The immunization may have multiple administrations of the vaccine, i.e., one or more immunizations via a mucosal route followed by one or more immunizations via a parenteral route or vice versa, to maximize both mucosal and systemic immune responses and protection against norovirus infections.Type: ApplicationFiled: May 18, 2020Publication date: November 5, 2020Inventors: RON COBB, MICHAEL SPRINGER, YAWEI NI
-
Publication number: 20190142930Abstract: An influenza vaccine comprising an influenza hemagglutinin-containing antigen which is subjected to a treatment at a suitable low pH or other suitable conditions to obtain a suitable degree of loss of potency, and the method of making it are provided. The vaccine not only induces an increased cross-reactive immune response and cross protection, but can also induce a strain-specific immune response and protection like current inactivated vaccines. A method of administering influenza vaccines is also provided to induce an increased cross-reactive immune response and cross protection, which is especially suitable for use in emergency situations such as a pandemic.Type: ApplicationFiled: January 14, 2019Publication date: May 16, 2019Inventors: Yawei Ni, Jianhua Guo
-
Publication number: 20180333478Abstract: Novel nanoparticle fusion proteins comprising proteins or peptides fused to Dps (DNA binding protein from starved cells) proteins are provided which bring forth distinct advantages for development of new and improved vaccines, diagnostic tests, and other biomedical products.Type: ApplicationFiled: February 9, 2018Publication date: November 22, 2018Inventor: Yawei Ni
-
Publication number: 20180243397Abstract: A dry powder norovirus vaccine is provided, which comprises at least two norovirus antigens representing different genogroups. The vaccine may be produced by formulation with a mixture of different antigens or combination of monovalent powders with each containing one antigen. The formulated vaccine is suitable for mucosal administration and soluble in aqueous solutions for parenteral administration. A method of immunization is also provided, which comprises at least one administration of the vaccine via mucosal and/or parental route. The immunization may have multiple administrations of the vaccine, i.e., one or more immunizations via a mucosal route followed by one or more immunizations via a parenteral route or vice versa, to maximize both mucosal and systemic immune responses and protection against norovirus infections.Type: ApplicationFiled: August 26, 2016Publication date: August 30, 2018Inventors: RON COBB, MICHAEL SPRINGER, YAWEI NI
-
Publication number: 20180147424Abstract: A nasal air filter comprises two hollow nostril adapters, a body, and a filter element. The body is panel shaped to conform to the bottom of the nose. The two hollow nostril adapters for insertion into nostrils at one end and attached side-by-side at the other end to one side of the body via corresponding thru holes on the body. The filter element is secured to the opposite side of the body, creating an open space between the bottom surface of the body and filter element to allow airflow through both nostril adapters and the entire surface area of the filter element. The filter element fitting within the raised edge of the body has a surface area larger than the combined area of the orifices of both nostrils, allowing efficient air filtering and ease of breathing. The device may comprise a nose cover connected around the top edge of the body shaped to conform to the top of the nose.Type: ApplicationFiled: April 23, 2016Publication date: May 31, 2018Applicant: KJ Biosciences LLCInventor: Yawei Ni
-
Patent number: 9889190Abstract: Novel nanoparticle fusion proteins comprising proteins or peptides fused to Dps (DNA binding protein from starved cells) proteins are provided which bring forth distinct advantages for development of new and improved vaccines, diagnostic tests, and other biomedical products.Type: GrantFiled: December 14, 2015Date of Patent: February 13, 2018Assignee: KJ Biosciences LLCInventor: Yawei Ni
-
Publication number: 20160095917Abstract: Novel nanoparticle fusion proteins comprising proteins or peptides fused to Dps (DNA binding protein from starved cells) proteins are provided which bring forth distinct advantages for development of new and improved vaccines, diagnostic tests, and other biomedical products.Type: ApplicationFiled: December 14, 2015Publication date: April 7, 2016Inventor: Yawei Ni
-
Patent number: 9241986Abstract: Novel nanoparticle fusion proteins comprising proteins or peptides fused to Dps (DNA-binding protein from starved cells) proteins are provided which bring forth distinct advantages for development of new and improved vaccines, diagnostic tests, and other biomedical products.Type: GrantFiled: December 22, 2010Date of Patent: January 26, 2016Assignee: KJ BIOSCIENCES LLCInventor: Yawei Ni
-
Publication number: 20150098966Abstract: An influenza vaccine comprising an influenza hemagglutinin-containing antigen which is subjected to a treatment at a suitable low pH or other suitable conditions to obtain a suitable degree of loss of potency, and the method of making it are provided. The vaccine not only induces an increased cross-reactive immune response and cross protection, but can also induce a strain-specific immune response and protection like current inactivated vaccines. A method of administering influenza vaccines is also provided to induce an increased cross-reactive immune response and cross protection, which is especially suitable for use in emergency situations such as a pandemic.Type: ApplicationFiled: May 14, 2013Publication date: April 9, 2015Applicant: KJ Biosciences LLCInventors: Yawei Ni, Jianhua Guo
-
Publication number: 20130171181Abstract: Novel nanoparticle fusion proteins comprising proteins or peptides fused to Dps (DNA-binding protein from starved cells) proteins are provided which bring forth distinct advantages for development of new and improved vaccines, diagnostic tests, and other biomedical products.Type: ApplicationFiled: December 22, 2010Publication date: July 4, 2013Applicant: KJ BIOSCIENCES LLCInventor: Yawei Ni
-
Patent number: 7705135Abstract: Pectins having a combination of unexpectedly high molecular weights and low degrees of methylation have been isolated from Aloe vera plants, are superior gel pectins for forming calcium cross-lined gels. Such pectins can be obtained by extracting homogenized Aloe Vera plants or portions thereof. These pectins can be used to prepare pharmaceutical compositions comprising pharmacological agents for application to animals and humans, so as to provide controlled release of the pharmacological agent.Type: GrantFiled: May 19, 2006Date of Patent: April 27, 2010Assignee: Nanotherapeutics, Inc.Inventors: Yawei Ni, Kenneth M. Yates, Ryszard Zarzycki
-
Patent number: 7691986Abstract: Pectins having a combination of unexpectedly high molecular weights and low degrees of methylation have been isolated. These high molecular weight, low degree of methylation pectins form gels at unexpectedly low concentrations. Such pectins can be obtained by extracting homogenized Aloe Vera plants or portions thereof. These pectins can be used to prepare pharmaceutical compositions comprising pharmacological agents encapsulated in a pectin gel, for application to animals and humans so as to provide controlled release of the pharmacological agent.Type: GrantFiled: April 23, 2003Date of Patent: April 6, 2010Assignee: Nanotherapeutics, Inc.Inventors: Yawei Ni, Kenneth M. Yates, Ryszard Zarzycki
-
Patent number: 7494669Abstract: In-situ gelation of a pectic substance. Composition, method of preparation, and method of use of a pectin in-situ gelling formulation for the delivery and sustained release of a physiologically active agent to the body of an animal. The pectin can be isolated from Aloe vera.Type: GrantFiled: August 29, 2003Date of Patent: February 24, 2009Assignee: Carrington Laboratories, Inc.Inventors: Yawei Ni, Kenneth M. Yates
-
Publication number: 20080026446Abstract: A composition combining an extracellular matrix-degrading protease and a growth factor related to epithelial cell functions together without inactivation or degradation of the growth factor by the protease. Preferably, the protease is plasmin/plasminogen or a related one, and the growth factor is KGF or a related one. The combination associates two independent, but synergistic functions essential to the re-epithelialization process or healing process, i.e, stimulating epithelial cell proliferation/differentiation and facilitating its migration by clearing the extracellular matrix components. The combination may be constructed in various ways and can be used to treat wounds or any other disease conditions involving cells of epithelial origin or any other cell types that the growth factor may affect.Type: ApplicationFiled: March 2, 2007Publication date: January 31, 2008Applicant: Carrington Laboratories, Inc.Inventors: Yawei Ni, Konnoth Yates
-
Patent number: 7202066Abstract: A composition combining an extracellular matrix-degrading protease and a growth factor related to epithelial cell functions together without inactivation or degradation of the growth factor by the protease. Preferably, the protease is plasmin/plasminogen or a related one, and the growth factor is KGF or a related one. The combination associates two independent, but synergistic functions essential to the re-epithelialization process or healing process, i.e, stimulating epithelial cell proliferation/differentiation and facilitating its migration by clearing the extracellular matrix components. The combination may be constructed in various ways and can be used to treat wounds or any other disease conditions involving cells of epithelial origin or any other cell types that the growth factor may affect.Type: GrantFiled: January 29, 2002Date of Patent: April 10, 2007Assignee: Carrington Laboratories, Inc.Inventors: Yawei Ni, Kenneth M. Yates
-
Publication number: 20060211653Abstract: Pectins having a combination of unexpectedly high molecular weights and low degrees of methylation have been isolated from Aloe vera plants, are superior gel pectins for forming calcium cross-lined gels. Such pectins can be obtained by extracting homogenized Aloe Vera plants or portions thereof. These pectins can be used to prepare pharmaceutical compositions comprising pharmacological agents for application to animals and humans, so as to provide controlled release of the pharmacological agent.Type: ApplicationFiled: May 19, 2006Publication date: September 21, 2006Inventors: Yawei Ni, Kenneth Yates, Ryszard Zarzycki